References: 

References

1. Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv. 2008;59:500-506.

2. Hamann J, Mendel R, Meier A, et al. “How to speak to your psychiatrist”: shared decision-making training for inpatients with schizophrenia. Psychiatr Serv. 2011;62:1218-1221.

3. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med. 2012;42:2145-2155.

4. Whitaker R. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses. 2004;62:5-13.

5. Substance Abuse and Mental Health Services Administration (SAMHSA). http://www.samhsa.gov/consumersurvivor/sdm/Print_Video/Print_and_Video.html. Accessed March 6, 2013.

6. Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? Br J Psychiatry. 2012;201:83-84.

7. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “just the facts”: what we know in 2008. Part 2. Epidemiology and etiology. Schizophr Res. 2008;102:1-18.

8. Keshavan MS, Amirsadri A. Early intervention in schizophrenia: current and future perspectives. Curr Psychiatry Rep. 2007;9:325-328.

9. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17:325-351.

10. Lieberman JA, Tollefson GD, Charles C, et al; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361-370.

11. MacDonald AS, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull. 2009;35:493-508.

12. Epright MC. Coercing future freedom: consent and capacities for autonomous choice. J Law Med Ethics. 2010;38:799-806.

13. Cohen P, Cohen J. The clinician’s illusion. Arch Gen Psychiatry. 1984;41:1178-1182.

14. Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144:727-735.

15. Bola JR, Mosher LR. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project. J Nerv Ment Dis. 2003;191:219-229.

16. Seikkula J, Alakare B, Aaltonen J. The comprehensive open-dialogue approach in Western Lapland: II. Long-term stability of acute psychosis outcome in advanced community care: the Western Lapland Project. Psychosis. 2011;3:192-204.

17. Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68:128-137.

18. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospital­isation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.

19. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69-77.

20. Marshall M, Rathbone J. Early intervention for psychosis. Schizophr Bull. 2011;37:1111-1114.

21. Friis S. Early specialised treatment for first-episode psychosis: does it make a difference? Br J Psychiatry. 2010;196:339-340.

22. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120-127.

23. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005;79:85-93.

24. Owens DC, Johnstone EC, Miller P, et al. Duration of untreated illness and outcome in schizophrenia: test of predictions in relation to relapse risk. Br J Psychiatry. 2010;196:296-301.

25. Bola JR, Kao DT, Soydan H. Antipsychotic medication for early-episode schizophrenia. Schizophr Bull. 2012;38:23-25.

26. Carpenter WT Jr, Gold JM, Lahti AC, et al. Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry. 2000;57:533-538.

27. McGorry PD. The concept of recovery and secondary prevention in psychotic disorders. Austr N Z J Psychiatry. 1992;26:3-17.

28. Reimer M. Treatment adherence in the absence of insight: a puzzle and a proposed solution. Philos Psychiatry Psychol. 2010;17:65-75.